Cyclic lactadherin peptide mimetics and their uses
Provided herein is a new class of cyclic lactadherin peptides (cLac) that mimic the natural phosphatidylserine (PS)-binding activity of the parent lactadherin protein. These cLacs are useful as small molecule indicators of early stage of apoptosis and of treatment efficacy evaluation.
1. A cyclic peptide comprising at least 11 but no more than 20 amino acid residues having the formula I:
wherein A 1 is either tryptophan or d-tryptophan;
wherein A 2 is biphenylalanine (“Bip”);
wherein A 4 is an amino acid with polar side chain that can form strong hydrogen bonding or salt bridge, the hydrogen bonding or salt bridge having a bond strength from 10 to >155 kJ mol −1 ;
wherein A 5 is a small hydrophobic amino acid selected from the group consisting of isoleucine, alanine, valine, leucine and methionine;
wherein A 6 is an amino acid with polar side chain that can form strong hydrogen bonding, the hydrogen bonding having a bond strength from 10 to >155 kJ mol −1 ;
wherein A 3 , A 7 and A 9 are neutral amino acid residues, wherein n=1-3, x=1-5 and y=2-6, and when there are multiples of A 3 , A 7 and A 9 , they can be the same amino acid residues or different amino acid residues;
wherein A 8 is a positively charged amino acid; and
wherein A 10 is an amino acid with a negatively charged side chain.
2. The cyclic peptide of claim 1 , wherein A 4 is selected from the group consisting of histidine, asparagine, glutamine, lysine, arginine and the respective analogues and derivatives thereof.
3. The cyclic peptide of claim 1 , wherein A 6 is selected from the group consisting of glutamine, tyrosine, serine, asparagine, histidine, cysteine and threonine.
4. The cyclic peptide of claim 1 , wherein A 3 , A 7 and A 9 are each individually selected from the group consisting of glycine, alanine, valine, leucine, isoleucine, cysteine, tyrosine, tryptophan, serine, threonine, proline, methionine, phenylalanine, glutamine, asparagine and propargyl glycine (ppG).
5. The cyclic peptide of claim 1 , wherein A 3 , A 7 and A 9 are each individually alanine or glycine.
6. The cyclic peptide of claim 1 , wherein A 8 is selected from the group consisting of lysine, arginine and the analogues and derivatives of these amino acids.
7. The cyclic peptide of claim 1 , wherein A 10 is selected from the group consisting of aspartic acid, glutamic acid and the analogues and derivatives of these amino acids.
8. The cyclic peptide of claim 1 , wherein the cyclic peptide binds to phosphatidylserine.
9. The cyclic peptide of claim 1 , wherein the cyclic peptide is selected from the group consisting of WBipGHIQGGRGGGD (SEQ ID NO: 1), WBipGHIQAGRGGGD (SEQ ID NO: 2), WBipGHIQGARGGGD (SEQ ID NO: 3), cLac-A5 or WBipGHIQGGRGGAD (SEQ ID NO: 4), WBipGHIQGGRGGGGD (SEQ ID NO: 5), WBipGHIQGGRGGGGGD (SEQ ID NO: 6), WBipGHppGQGGRGGGD (SEQ ID NO: 7), WBipGHIQGppGRGGGD (SEQ ID NO: 8), WBipGHIQGRGGGD (SEQ ID NO: 9), WBipGHIQGGGRGGGD (SEQ ID NO: 10), WBipGHIQGppGRGGAD (SEQ ID NO: 11), d-WBipGHIQGGRGGGD (SEQ ID NO: 12) or a peptide variant thereof.
10. The cyclic peptide of claim 1 , further comprising a label.
11. A composition comprising a cyclic peptide of claim 1 and a pharmaceutically acceptable carrier.
12. A kit comprising a cyclic peptide of claim 1 and instructions for using the cyclic peptide or composition to detect phosphatidylserine exposure or apoptosis in a sample.
13. A method of detecting phosphatidylserine exposure on a cell, comprising contacting a biological sample with the cyclic peptide of claim 1 and measuring the cyclic peptide attached to the biological sample, wherein the amount of cyclic peptide attached is above a reference level indicates the presence of phosphatidylserine exposure on a cell in the biological sample.
14. A method of detecting apoptosis of a cell, comprising contacting a biological sample with the cyclic peptide of claim 1 and measuring the cyclic peptide attached to the biological sample, wherein the amount of cyclic peptide attached is above a reference level indicates the presence of apoptosis in the biological sample.
15. A method of detecting apoptosis in a tissue in a subject in need thereof, contacting the tissue with the cyclic peptide of claim 1 and measuring the cyclic peptide attached to the tissue, wherein the amount of cyclic peptide attached is above a reference level indicates the presence of apoptosis in the tissue.
16. A kit comprising a composition of claim 11 and instructions for using the cyclic peptide or composition to detect phosphatidylserine exposure or apoptosis in a sample.
17. A method of detecting phosphatidylserine exposure on a cell, comprising contacting a biological sample with a composition of claim 11 and measuring the cyclic peptide attached to the biological sample, wherein the amount of cyclic peptide attached is above a reference level indicates the presence of phosphatidylserine exposure on a cell in the biological sample.
18. A method of detecting apoptosis of a cell, comprising contacting a biological sample with a composition of claim 11 and measuring the cyclic peptide attached to the biological sample, wherein the amount of cyclic peptide attached is above a reference level indicates the presence of apoptosis in the biological sample.
19. A method of detecting apoptosis in a tissue in a subject in need thereof, contacting the tissue with or a composition of claim 11 and measuring the cyclic peptide attached to the tissue, wherein the amount of cyclic peptide attached is above a reference level indicates the presence of apoptosis in the tissue.